Is Biocon a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Biocon Ltd is a average quality company .

Is Biocon undervalued or overvalued?

The key valuation ratios of Biocon Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Biocon share price return in the past 10 years?

Biocon Ltd share price has appreciated 16.6% annually (CAGR) over the past ten years.

Is Biocon a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Biocon Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Biocon Ltd - Stock Valuation and Financial Performance

Name: Biocon
Brand: Biocon

BSE: 532523 | NSE: BIOCON | Pharmaceuticals & Drugs | Mid Cap

Place order

Biocon Share Price

₹335.95 -14.40 -4.11%
as on 20-Dec'24 16:59

10 Year X-Ray of Biocon:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	16.8%	16.5%	12.4%	8.3%	4.5%	6.1%	7.5%	4.7%	1.7%	29.8%	-
Value Creation Index ⓘ	0.2	0.2	-0.1	-0.3	-0.6	-0.5	-0.3	-0.6	-0.9	1.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	2,203	2,242	2,302	2,588	2,419	1,786	1,988	2,028	1,738	1,993	2,131
Sales YoY Gr.	-	1.8%	2.7%	12.4%	-6.5%	-26.2%	11.4%	2%	-14.3%	14.7%	-
Adj EPS ⓘ	2.6	3.1	2.4	4.4	1.7	1.9	2.5	2.4	0.6	6.8	0.4
YoY Gr.	-	21.7%	-25.2%	88.9%	-61.3%	9.3%	33%	-4.8%	-74%	1003.2%	-
BVPS (₹) ⓘ	19.2	21.3	49.6	54.1	55.7	58.8	62.1	65	66.6	90	90.7
Adj Net Profit ⓘ	309	376	282	533	207	225	300	285	74.6	822	42
Cash Flow from Ops. ⓘ	186	125	209	186	355	110	387	571	47.6	219	-
Debt/CF from Ops. ⓘ	0.7	0.7	1.8	0.7	0.4	0.7	0	0	1.6	5.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-1.1%	-3.8%	0.1%	14.7%
Adj EPS ⓘ	11.4%	31.8%	39.9%	1003.2%
BVPSⓘ	18.7%	10.1%	13.2%	35.1%
Share Price	16.6%	3%	-1.4%	36.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	13.4	15.1	6.6	8.5	3.1	3.3	4.1	3.7	0.9	8.6	0.4
Op. Profit Mgn % ⓘ	-2.9	19.2	17.9	23.8	13.1	11.9	14.2	15.9	3.5	1.1	9.7
Net Profit Mgn % ⓘ	14.1	16.8	12.3	20.6	8.5	12.6	15.1	14.1	4.3	41.2	2
Debt to Equity ⓘ	0.1	0	0.1	0	0	0	0	0	0	0.1	0.2
Working Cap Days ⓘ	227	244	243	240	295	433	376	296	321	305	210
Cash Conv. Cycle ⓘ	79	90	88	85	111	171	141	95	154	150	137

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 39.86%

Return on Equity has declined versus last 3 years average to 0.40%

Sales growth has been subdued in last 3 years 0.08%

Sales growth is not so good in last 4 quarters at 1.83%

Latest Financials - Biocon Ltd.

	Standalone	Consolidated
TTM EPS (₹)	0.4	12
TTM Sales (₹ Cr.)	2,131	14,334
BVPS (₹.) ⓘ	90.7	174.9
Reserves (₹ Cr.) ⓘ	10,235	20,392
P/BV ⓘ	3.70	1.92
PE ⓘ	958.06	28.03

From the Market
52 Week Low / High (₹)	239.45 / 395.65
All Time Low / High (₹)	14.43 / 487.70
Market Cap (₹ Cr.)	40,334
Equity (₹ Cr.)	600.3
Face Value (₹)	5
Industry PE ⓘ	44.3

Management X-Ray of Biocon:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Biocon

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Biocon

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	2,242	2,302	2,588	2,419	1,786	1,988	2,028	1,738	1,993	2,127
Operating Expenses ⓘ	1,814	1,889	1,997	2,106	1,576	1,707	1,717	1,677	1,972	1,912
Manufacturing Costs	363	362	367	458	370	418	388	408	440	416
Material Costs	947	988	1,035	1,049	789	828	798	808	984	935
Employee Cost	284	322	365	409	289	345	390	368	434	452
Other Costs ⓘ	219	218	229	190	128	116	140	93	115	109
Operating Profit ⓘ	428	413	591	313	210	282	311	61	21	216
Operating Profit Margin (%)	19.1%	17.9%	22.9%	13.0%	11.8%	14.2%	15.3%	3.5%	1.0%	10.1%
Other Income ⓘ	151	182	99	130	109	206	152	187	274	240
Interest ⓘ	1	2	4	1	3	1	0	0	70	199
Depreciation ⓘ	128	140	151	136	92	98	104	108	117	121
Exceptional Items ⓘ	-22	106	0	0	199	160	0	0	2,863	15
Profit Before Tax ⓘ	428	559	536	306	423	548	359	140	2,971	150
Tax ⓘ	67	191	17	67	45	112	78	54	123	31
Profit After Tax	361	369	519	239	378	436	281	86	2,848	119
PAT Margin (%)	16.1%	16.0%	20.1%	9.9%	21.2%	21.9%	13.8%	5.0%	142.9%	5.6%
Adjusted EPS (₹)	3.0	3.1	4.3	2.0	3.2	3.6	2.3	0.7	23.7	1.0
Dividend Payout Ratio (%)	28%	27%	12%	25%	16%	0%	0%	70%	6%	50%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	2,558	5,953	6,497	6,689	7,056	7,454	7,805	8,000	10,808	10,832
Share Capital ⓘ	100	100	100	300	300	600	600	600	600	600
Reserves ⓘ	2,458	5,853	6,397	6,389	6,756	6,854	7,205	7,399	10,207	10,232
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	68	362	132	67	1	1	1	76	1,298	2,041
Long Term Debt	11	137	132	67	1	1	0	76	1,298	2,041
Short Term Debt	56	226	0	0	0	0	1	0	0	0
Trade Payables	301	394	451	580	644	521	372	381	457	448
Others Liabilities ⓘ	406	389	284	289	337	156	249	293	445	441
Total Liabilities ⓘ	3,333	7,098	7,364	7,625	8,039	8,131	8,427	8,749	13,007	13,761
Fixed Assets
Gross Block	1,832	1,934	2,082	2,182	2,527	1,885	1,988	2,167	2,369	2,476
Accumulated Depreciation	918	1,041	1,188	1,323	1,467	1,164	1,260	1,363	1,470	1,576
Net Fixed Assetsⓘ	914	894	894	859	1,059	721	729	805	899	900
CWIP ⓘ	58	172	241	319	255	152	179	285	344	560
Investmentsⓘ	165	3,809	3,888	4,199	4,093	4,953	5,413	5,280	9,271	9,319
Inventories	406	505	540	562	802	535	431	542	560	665
Trade Receivables	555	504	798	740	902	573	605	701	658	1,048
Cash Equivalents	621	643	383	197	356	375	601	689	720	586
Others Assetsⓘ	614	572	620	750	572	823	469	448	555	684
Total Assets ⓘ	3,333	7,098	7,364	7,625	8,039	8,131	8,427	8,749	13,007	13,761

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	125	209	186	355	110	387	571	48	219	-123
PBT ⓘ	428	559	536	306	552	560	359	140	2,971	150
Adjustment ⓘ	4	-88	111	65	-112	-68	118	108	-2,727	112
Changes in Working Capital ⓘ	-224	-58	-341	72	-194	-14	156	-172	16	-358
Tax Paid ⓘ	-83	-205	-121	-88	-137	-91	-61	-28	-41	-28
Cash Flow From Investing Activity ⓘ	146	-321	110	-556	311	-213	-711	-306	-1,178	-296
Capex	-70	-243	-231	-170	-258	-192	-152	-245	-264	-306
Net Investments	-86	-365	243	-352	265	-991	-732	4	-376	554
Others ⓘ	303	286	98	-34	304	971	172	-65	-538	-544
Cash Flow From Financing Activityⓘ	-158	73	-238	-55	-208	-129	28	112	1,039	344
Net Proceeds from Shares ⓘ	0	10	19	27	32	32	40	43	30	31
Net Proceeds from Borrowing ⓘ	-15	118	-8	-1	-67	-67	-1	73	1,187	500
Interest Paid ⓘ	-1	-1	-4	-1	-3	-1	0	-1	-51	-6
Dividend Paid ⓘ	-100	-211	0	-69	-69	-60	0	0	-60	-180
Others ⓘ	-43	157	-246	-10	-101	-33	-11	-2	-66	-1
Net Cash Flow ⓘ	113	-40	58	-255	212	45	-112	-146	81	-76

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	14.87	8.66	8.34	3.62	5.51	6.01	3.68	1.09	30.29	1.1
ROCE (%)	16.49	12.43	8.28	4.53	6.06	7.46	4.65	1.74	29.84	2.77
Asset Turnover Ratio	0.69	0.45	0.36	0.32	0.23	0.25	0.24	0.2	0.18	0.16
PAT to CFO Conversion(x)	0.35	0.57	0.36	1.49	0.29	0.89	2.03	0.56	0.08	-1.03
Working Capital Days
Receivable Days	84	83	91	116	168	135	106	137	124	146
Inventory Days	61	71	73	83	139	123	87	102	101	105
Payable Days	110	128	149	179	283	257	204	170	155	177

Biocon Ltd Stock News

Biocon Ltd FAQs

What is the share price of Biocon?

Company share prices are keep on changing according to the market conditions. The closing price of Biocon on 20-Dec-2024 16:59 is ₹335.9.

What is the market cap of Biocon?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Biocon stood at ₹40,334.2.

What is the P/E ratio of Biocon?

The latest P/E ratio of Biocon as of 20-Dec-2024 16:59 is 958.1.

What is the P/B ratio of Biocon?

The latest P/B ratio of Biocon as of 20-Dec-2024 16:59 is 3.70.

What is the 52-week high and low of Biocon?

The 52-week high of Biocon is ₹395.6 and the 52-week low is ₹239.4.

What is the TTM revenue of Biocon?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Biocon is ₹2,131 ( Cr.) .

About Biocon Ltd

Biocon Limited is engaged in the manufacture of biotechnology products and research services. The Company is a public limited company incorporated and domiciled in India. The Company’s shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) in India.

Business area of the company

The company is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Products

Generics
Biosimilars
Branded Formulations
Novel Biologics
Awards & Recognition

1985:

Export Performance Award, Karnataka State Financial Corporation (KSFC)
National Award for Best Small Industry, Government of India

2000:

Technology Pioneer Recognition, World Economic Forum

2001:

Biotech Product, Process Development and Commercialisation Award, Department of Biotechnology, Ministry of Science and Technology, Government of India

2003:

Bio-Business Award for bio-entrepreneurship, Rabo India
Express Pharma Pulse Award for excellence in the pharmaceutical industry

2004:

Best Reinvention of HR Function Award, Indira Group, Mumbai
Best Employer Of India Award, Hewitt

2006:

Best IT User Award in the Pharmaceutical Sector, NASSCOM

2007:

Syngene receives ‘BioServices Company of the Year’, BioSpectrum Awards
Biocon's BIOMAb EGFR wins ‘Product of the Year’, BioSpectrum Awards

2008:

Biocon is ranked among the Top 20 Global Biotechnology Companies
Biocon is the 7th largest Biotech Employer in the world

2009:

Biocon among Top 20 Indian Companies in Forbes ‘Best Under A Billion’ list
Biocon wins Bio-Excellence Award for Outstanding Achievement in the Healthcare Sector at Bangalore Bio
Syngene wins Bio-Excellence Award for Outstanding Achievement in the Biotech Service Sector at Bangalore Bio
Biocon bags IDMA 'Best Patent of the Year' Award
Biocon wins prestigious BioSingapore Asia Pacific Biotechnology Award for Best Listed Company

2011:

Biocon wins Biospectrum BioPharma Company of the Year Award
Biocon wins Best Design and Information Award for the Healthcare Sector at Bangalore India Bio

2012:

Biocon features in Top Twenty Global Employers in Biopharma by Science Magazine
Biocon wins Excellence in Environmental Management Award
Biocon wins Best Exhibitor Award in the category of Biocontent and Information at Bangalore India Bio
Biocon wins Golden Peacock National Quality Award

2013:

Biocon makes it to the Top Ten Most Admired Companies in the Pharma & Healthcare Sector, Fortune India Magazine, July
Biocon wins ABLE 10th Anniversary Award for Outstanding Contribution to Biopharmaceuticals for the decade, 2002-2012
Biocon wins Best Design and Innovation Exhibitor Award at Bangalore India Bio
Biocon Ranked No. 6 among Top 20 Global Biotech Employers by the Science Magazine

2014:

Biocon Foundation gets 'Asia Best CSR Practices Award 2014' for 'Cervical Cancer Screening Programme'
Biocon wins Thomson Reuters India Innovation Awards 2014
Biocon Foundation wins 'Healthcare CSR of the Year'

2015:

Biocon wins Golden Peacock Award - 2014 in the 'Corporate Social Responsibility'
Biocon wins the 'Greentech Environment Gold Award'
Biocon Foundation wins 'WHO - India Public Health Champion Award 2015'
Biocon bags 'The Best in-house IP team of the Year' Award at the Global IP Conclave 2015
Biocon wins prestigious ‘UNNATHA SURAKSHA AWARD’ for Safety & Environment Excellence
With 'Hall of Fame 2015', Biocon sweeps CIO100 2015 Award with three outstanding honours
Biocon bags Pharmexcil Gold Patent Award 2014-15
Biocon is the Only Asian Company to be ranked in Top 20 Global Biotech Employers for 2015
Biocon wins Procurement Excellence Awards 2015 for ‘Best in Class Excellence in Cost Management’
Biocon awarded with India's most coveted Packaging Award for Branded Formulation Products
Biocon receives Greentech Environment Award 2015 for excellence in Environment Management in Indian Pharma Industry

2016:

Biocon features in Asia IP Elite 2016 List
Biocon recognised for 'Corporate Best HR Practices' at NHRD
Biocon's Novel Diabetes Education Initiative for Medical Practitioners 'ABIDE' awarded by RSSDI
Biocon ranked among Global Top Ten Biotech Employers; the only Asian company to feature in 2016 rankings.
Biocon wins Frost & Sullivan India Best Practices Award 2016 for ‘Biotechnology Company of the Year’
Biocon awarded as ‘The Company with Great Managers’
Biocon wins Gold Award for ‘Company of the Year’ in B2B Marketing at the SABRE Awards, South Asia 2016
Biocon wins CII Excellence Award for Best EHS practices in Pharma
Biocon wins National Award for Excellence in Training & Development in Pharma Sector for 2016
Biocon conferred prestigious status of ‘Transformation Icon’ & ‘Healthcare & Pharma Icon’ for IT Excellence at CIO Awards 2016
Biocon felicitated at World HRD Congress 2016 for Excellence in Human Resource Management

2017:

Biocon was honoured with the prestigious Bio-Pharma Excellence Award at Bangalore Technology Summit.
Biocon featured in ‘Asia IP Elite’ list for the second consecutive time by world’s leading IP magazine IAM at IPBC Asia 2017 held in Tokyo.
Biocon ranked 09 among Global Biotech Employers for 2017 by Science magazine. The only Asian company to feature in Top 20.
Biocon was conferred with the ´The Star Exporter Award´ by the Federation of Karnataka Chambers of Commerce & Industry (FKCCI).
Biocon’s Corporate Communications Team has been ranked No. 13 amongst Top 30 teams in India by Reputation Today magazine.

2018:

Biocon honoured at the IPBC Asia Award 2018 for the third consecutive year by world’s leading IP Business information provider IAM.
Biocon conferred at the prestigious CII Industrial Intellectual Property Awards 2018 for having The Best Trademark Portfolio (2013-2018) in the Large Industries (Life Sciences) category.
Biocon honoured at Pharmexcil Outstanding Exports Award 2017-18 for outstanding contribution to India’s Pharmaceutical Exports during the year 2017-18.
Biocon’s Learning and Development Team felicitated with 2 Gold Category Awards at TISS-Leapvault CLO Summit 2018.
Biocon felicitated at World HRD Congress 2018 for ‘Excellence in Training & Development’. The excellent L&D initiatives contributed to the company being ranked amongst the Global Top 10 Biotech Employers.
Biocon recognised for its SFE Digital Initiative, in BFI Conferred with DigiPharmaX 2017 Award. Biocon received the award under the category of ‘Leveraging technology for use of both digital and onsite promotion for integrated digital marketing’.

2019:

Biocon's APIs Facility in Hyderabad awarded the Annual Greentech Environment Award for ‘Outstanding Achievements in Environment Management in the Pharmaceutical Sector’ during the 19th Annual Greentech Sustainability Conference.
Biocon wins 2 awards at the TISS-Leapvault CLO Summit: ‘Learning and Development Team of the Year’ and ‘Best Diversity & Inclusion Program’.
Biocon wins Unnatha Suraksha Puraskara given by National Safety Council (NSC), Karnataka Chapter for demonstrating excellence in Industrial Safety & Occupational Health Management across its operations.
Biocon moves up to Rank No. 6 on Science Careers’ Top 20 Global Pharma and Biotech Employers List 2019.
Biocon Biologics has been recognised as ASIA IP ELITE 2019 at IPBC Asia 2019 held in Tokyo, making it the 4th consecutive year that Biocon Group has been awarded by the world’s leading IP magazine, IAM (Intellectual Asset Magazine).
Biocon showcases a strong presence at Bengaluru Tech Summit 2019 and wins the ‘Best Exhibitor Award’.
Biocon Biologics BFI Learning & Development Team wins the ‘Best Training & Development Award’ at L&D World Summit & Awards, Bengaluru.
Biocon's Global Communications Team recognised among Top 30 in India.
Biocon wins ‘Best Initiative in Employee Wellness’ at the 3rd edition of the Employee Engagement Leadership Awards.
Biocon recognised for the ‘Best Initiative in Employee Wellness’ at the 3rd edition of the Employee Engagement Leadership Awards, for its comprehensive approach to ensure physical, emotional, social and environmental well-being.
Biocon conferred the IDMA Margi Memorial ‘Best Patent Award’ in the ‘Biotech’ category in an event organised by the Indian Drug Manufacturers’ Association (IDMA).

2020:

Biocon bags ‘Best Biotech Patents Award 2018-19’ by Indian Drug Manufacturing Association (IDMA) at the IDMA 58th Annual Day celebration.
Biocon's Biowin HR team won awards in 4 categories such as Women L & D Programs, Diversity Policies, Large Enterprise and Diversity Programs.
Biocon's EHS (Environment, Health & Safety) team received the State Level Award in ‘Implementation of Best Safety Practices’ from Department of Factories, Govt. of Karnataka.

Milestones

1978: Biocon India Private Limited is incorporated as a joint venture between Kiran Mazumdar-Shaw and Biocon Biochemicals Limited Ireland. Starting with three employees in a rented shed in Koramangala, suburban Bangalore. Biocon began manufacturing and exporting Papain, a plant enzyme, and Isinglass, a marine hydrocolloid - both, key products for the brewing industry.
1979: Biocon’s first export was Papain, a plant enzyme derived from Papaya, to U.S. and Europe, signalling the company's ambition to produce high quality, world class products in India for global markets.
1980: Biocon acquires a 20-acre plot on Hosur Road, Bangalore to expand operations. On March 8, 1980, the foundation stone was laid for the building that currently houses the company’s corporate office.
1981: Biocon decides to move beyond its frugal operations in rented premises and starts building its own integrated campus at 20th KM, Hosur Road, Electronics City, Bangalore.
1983: Biocon’s new campus at 20th KM, Hosur Road, Electronics City, Bangalore is inaugurated by Irish Ambassador H.E. Bernard McHugh. Manufacturing activity shifted from the rented shed to the new site. R&D was also initiated.
1984: Biocon established its R&D division, which initially focused on the development of solid state fermentation technology to develop novel enzymes.
1989: Biocon Biochemicals Limited, Ireland, including its subsidiaries, are acquired by Unilever Plc. and merged with its wholly-owned subsidiary Quest International, The Netherlands. Biocon India begins producing enzymes for Unilever’s food businesses.
1990: Biocon scales up its in-house research program based on a proprietary solid state fermentation technology through a new subsidiary Biochemizyme Limited to scale up from pilot to plant level.
1993: Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany, making it the first life sciences company in India to get the ISO 9001 Certification.
1994: Syngene is incorporated as a Custom Research Organisation (CRO) in 1994 to provide efficient, high-quality, cost-effective research & development services in chemistry and biology to the global pharmaceutical industry.
1995: Unilever acquires 50% stake in Biochemizyme and creates Biocon Quest India Limited (BQIL), with Biocon and Unilever holding 50% stake each in the entity. A four-fold expansion of Biochemizyme’s solid state fermentation capacity aims to produce a range of fungal enzymes for the food and pharmaceutical industry.
1998: Kiran Mazumdar-Shaw and John Shaw buy out Unilever’s share in Biocon India Limited making it an independent, privately owned company.
1999: Nobel Laureate Prof. James D. Watson, remembered for co-discovering DNA’s double-helix structure, visits Biocon.
2000: Biocon establishes Clinigene as India's first Clinical Research Organisation to develop world-class capabilities for clinical research and related activities. Clinigene, a 100% subsidiary of Biocon, starts providing clinical research services to domestic and multinational companies.
2000: PlaFractor, Biocon’s patented fermentation reactor, is commissioned. The indigenous PlaFractor fermentation platform proved a commercial success as Biocon was the first company to make Mycophenolate Mofetil using this technology in 2000.
2000: Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals.
2001: Biocon is the first company globally to get U.S. FDA approval for making Lovastatin API through an innovative solid state fermentation technology.
2001: Biocon’s proprietary bioreactor PlaFractor is granted a U.S. and worldwide patent.
2002: Biocon establishes a joint venture company, Biocon Biopharmaceuticals Private Limited, with CIMAB S.A., a Cuban biotechnology company, to manufacture biologicals developed by CIMAB, including Nimotizumab & Itolizumab monoclonal antibodies.
2004: Biocon is the first company in the world to commercialise recombinant human insulin (rh-insulin), Insugen, using a novel Pichia pastoris yeast expression system.
2004: Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO.
2006: Biocon Park, India’s first private Biotechnology SEZ, inaugurated.
2006: First company in India to launch a novel biologic, Nimotuzumab.
2006: India's largest multi-product Biologics facility inaugurated.
2007: Biocon divests enzymes business.
2008: Biocon acquires stake in AxiCorp GmbH, a German pharmaceutical company.
2009: Biocon, Mylan enter strategic global partnership for development of biosimilars.
2009: Biocon launched Insulin Glargine under the brand name Basalog in India, providing diabetes patients with an advanced, affordable insulin therapy.
2009: Biocon Bristol-Myers Squibb Research Centre (BBRC) inaugurated.
2010: Biocon and Pfizer enter into a strategic global agreement.
2011: Biocon starts work on the largest integrated insulins facility in Asia.
2011: Biocon launches INSUPen for patients in India.
2012: Biocon Research Centre Inaugurated.
2013: World’s first anti-CD6 monoclonal antibody Itolizumab commercialised in India.
2013: Biocon House inaugurated.
2013: Biocon establishes Biocon Academy under its CSR agenda.
2014: Biocon introduces world’s first biosimilar Trastuzumab, CANMAb, in India.
2015: Biocon’s research services subsidiary, Syngene, debuts on the Indian stock market.
2015: Biocon’s new insulin devices facility inaugurated in Bangalore.
2016: Biocon Gets its First Generic Formulation Approval in EU.
2016: First biosimilar from India to be approved in Japan.
2017: First company from India to get U.S. FDA approval for a biosimilar.
2017: Biocon’s first overseas facility in Malaysia starts operations.
2017: Biocon outlicenses Itolizumab to Equillium for U.S., Canada.
2017: Biocon launches its biosimilar Bevacizumab in India.
2018: First company from India to have biosimilar commercialised in U.S.
2018: Biocon and Mylan’s biosimilar Insulin Glargine, Semglee, receives European approval for commercialisation.
2018: Biocon, Sandoz enter global partnership for next-gen biosimilars.
2018: Two biosimilars get marketing authorisation in EU.
2019: Biosimilars business consolidated under independent entity Biocon Biologics.
2019: Biocon becomes the first Indian player to launch biosimilar Trastuzumab, Ogivri, in the U.S. through partner Mylan.
2019: Bicara Therapeutics is incorporated as a wholly owned subsidiary of Biocon in Boston, U.S., to focus on developing a pipeline of bi-functional antibodies that exploit the advances in immuno-oncology.
2020: True North makes a primary equity investment in Biocon Biologics.
2020: Itolizumab Gets DCGI Nod for Restricted Emergency Use in Moderate to Severe COVID-19 Patients.
2020: Tata Capital picks up minority stake in Biocon Biologics.
2020: Biocon and Mylan achieve the key milestone of receiving U.S. FDA approval and bringing to market both the vial and pen presentations of Semglee (insulin glargine injection), the first for any company following the reference product.